Index · Artikel · Roche Q1 sales solid as Illumina bid battle rages

Roche Q1 sales solid as Illumina bid battle rages

2012-04-12 3
   
Advertisement
résuméZURICH Swiss drugmaker Roche said it would have to rethink its tactics if shareholders of reluctant U.S. bid target Illumina did not back its approach as it reported strong first-quarter pharmaceutical sales helped by top cancer drugs. Genetics speci
Advertisement

Roche Q1 sales solid as Illumina bid battle rages


ZURICH Swiss drugmaker Roche said it would have to rethink its tactics if shareholders of reluctant U.S. bid target Illumina did not back its approach as it reported strong first-quarter pharmaceutical sales helped by top cancer drugs.

Genetics specialist Illumina has rejected Roche's $6.8 billion sweetened takeover offer and urged investors to vote against Roche's bid to get its own nominees on to the U.S. firm's board at a meeting on April 18 to push for talks.

Chief Executive Severin Schwan told journalists on Thursday that Roche would have to consider "all its options" if Illumina shareholders voted against its proposals at that meeting.

Roche's efforts to get its slate of directors elected to Illumina's board look to be a long shot after three proxy advisory firms have recommended that shareholders back Illumina's nominees.

"If Illumina were to engage with us, we would consider any information supporting Illumina`s contention that our offer undervalues the company and its prospects," Schwan said in a statement, adding that publicly available information did not justify a price above $51 per share.

His comments echo those made in a letter to Illumina shareholders late on Wednesday in which Schwan also ridiculed Illumina's claim to be "the Apple of the genomics business".

Roche said its $51-per-share offer for Illumina - raised from an initial $44.50 - should be "more than enough" to begin negotiations with the maker of genetic analysis equipment that can help better identify which patients benefit from drugs.

Illumina's shares fell 3.5 percent to $50.75, as speculation faded of Roche hiking its offer again by much.

But Bernstein analyst Timothy Anderson said Schwan's comments still suggested Roche was willing to raise its bid, "perhaps through some sort of flexible bid, similar to Sanofi's acquisition of Genzyme?"

Sanofi's 2011 deal to buy Genzyme included contingent value rights (CVRs) or milestone fees tied to the company meeting certain obligations and the future performance of some of its drugs.

Roche, the world's largest maker of cancer drugs, said its first-quarter sales fell 1 percent to 11.03 billion Swiss francs ($12.05 billion), but rose 2 percent at constant exchange rates, meeting the average analyst forecast in a Reuters poll.

Sales at the dominant pharmaceuticals division beat forecasts as a return to growth for key cancer drug Avastin and strong growth of hepatitis drug Pegasys helped counterbalance hits from the strong franc and cuts to health budget spending.

"The Q2 2012 outperformance, driven by a stronger-than-expected performance of large cancer drugs and Pegasys, particularly in the USA, compensating for ongoing pricing pressure in Europe should provide confidence," said Helvea analyst Karl-Heinz Koch.

Roche shares closed up 1.56 percent, outperforming a 0.8 percent firmer European health sector.

The bid for Illumina is part of Roche's move into more personalized medicines helped by advances in genetics research, and is spurred by the challenges facing the global drugs industry, including patent expiries and government price cuts.

Roche is better positioned than most to weather the storm, however, since its top-selling cancer medicines do not face imminent generic competition.

Even so, it has not been able to escape the impact of austerity measures in Europe, where many countries have imposed big cuts in their medicine bills. Roche said those pricing effects shaved 1.5 percent off European sales in the quarter.

Roche reiterated that it hoped sales would grow in the low-to-mid single digit range at constant exchange rates this year, while core earnings would grow in the high single-digits.

Sales of Avastin rose 1 percent to 1.385 billion francs, meeting average analyst forecasts and reversing several quarters of decline for what used to be Roche's top-selling drug. Roche reiterated its peak sales forecast of 7 billion francs.

Avastin, hit last year when the United States revoked its conditional approval as a treatment for breast cancer, has been overtaken by Roche's other cancer drugs Rituxan and Herceptin, which both saw sales grow 7 percent in the quarter.

"Oncology revenues (Avastin, Herceptin, Rituxan) overall performed about 1 percent better than expected," said Vontobel analyst Andrew Weiss.

Roche said Avastin's growth was mainly driven by increased use in lung and colon cancer, with growth in Japan and emerging markets offsetting a modest decline in western Europe, while sales stabilized in the United States.

Roche expects Avastin sales to continue to grow "in the next few quarters", Pascal Soriot, head of the pharmaceuticals division, told a conference call for analysts.

Another highlight was a 32 percent jump in sales for hepatitis drug Pegasys, driven by increased demand in the United States for use in triple combination therapy.

(Reporting by Emma Thomasson; Editing by Mark Potter and Helen Massy-Beresford)

  • Roche Q1 sales solid as Illumina bid battle rages

    Roche Q1 sales solid as Illumina bid battle rages
    ZURICH Swiss drugmaker Roche said it would have to rethink its tactics if shareholders of reluctant U.S. bid target Illumina did not back its approach as it reported strong first-quarter pharmaceutical sales helped by top cancer drugs. Genetics speci
    2012-04-12 ROCHE
  • Exclusive: Roche exploring sale of diabetes device unit

    Exclusive: Roche exploring sale of diabetes device unit
    NEW YORK Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased competition and reimbursement pressure. The d
    2013-05-15 ROCHESALE
  • Roche digs in for long fight for Illumina

    Roche digs in for long fight for Illumina
    ZURICH Swiss drugmaker Roche is digging in for a long fight after gene sequencing company Illumina rejected its $5.7 billion hostile takeover bid as inadequate and said it would be more successful on its own. Roche, which offered to pay $44.50 per sh
    2012-02-08 ROCHEILLUMINA
  • Roche boosted by strong drug sales in U.S. and China

    Roche boosted by strong drug sales in U.S. and China
    ZURICH Strong demand for Roche's specialty cancer medicines, many of which are bought privately in emerging markets, has helped it defy an expected slowdown in sales in China following a crackdown on sales practices there. The Swiss group on Thursday
    2013-10-17 ROCHERESULTS
  • Rivals see no need to match Roche's big gene bet

    Rivals see no need to match Roche's big gene bet
    DAVOS, Switzerland Roche Holding AG's rivals Sanofi SA and Novartis AG see no need to match the Swiss drug maker in buying a gene-decoding business like Illumina Inc and reckon they can do partnerships instead. The relaxed attitude in the face of Roc
    2012-01-27 ROCHEDAVOSRIVALS
  • Roche tops forecast as new cancer drugs gain momentum

    Roche tops forecast as new cancer drugs gain momentum
    BASEL, Switzerland Swiss pharmaceuticals firm Roche beat first-half profit forecasts as strong sales of its mainstay cancer drugs and some new treatments supported its view that it can withstand competition from cheap, copycat drugmakers. The results
    2013-07-25 ROCHERESULTS
  • Analysis: Pharma's woes not over, more restructuring seen

    Analysis: Pharma's woes not over, more restructuring seen
    NEW YORK Global drugmakers have cut tens of thousands of jobs ahead of patent expirations on their top-selling products, and the pain is not yet over. Divisions across these companies -- from sales to research to manufacturing -- are still seen as vu
    2010-11-28 DRUGSRESTRUCTURING
  • Roche in $5.7 billion bid for gene decoder Illumina

    Roche in $5.7 billion bid for gene decoder Illumina
    ZURICH/LONDON Swiss drugmaker Roche Holding AG ROG.VX has offered $5.7 billion in cash in a hostile bid to take over Illumina Inc (ILMN.O), and investors are already betting that the U.S. gene sequencing company will command a significantly higher pr
    2012-01-25 ROCHEILLUMINA
  • Roche sees more cancer success as sales top forecast

    Roche sees more cancer success as sales top forecast
    ZURICH Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments helped it to top forecasts in the third quarter. Most of Roche's best-se
    2012-10-16 ROCHE
  • Roche and Novartis face off in biosimilar drug battle

    Roche and Novartis face off in biosimilar drug battle
    ZURICH Switzerland's biggest drugmakers are clashing over cheaper copies of pricey biotech drugs - one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche. With a copycat of Roche's blood cancer drug Rituxan pen
    2016-05-30 DRUGMAKERSSWISS
  • Illumina board rejects sweetened Roche offer

    Illumina board rejects sweetened Roche offer
    n">Illumina Inc said on Monday that its board unanimously rejected Roche Holding's increased offer to buy the genetic sequencing company for $51 per share, or about $6.7 billion, saying it dramatically undervalued the company. Illumina management
    2012-04-03 ROCHEILLUMINA
  • Roche calls offer for Illumina "starting point"

    Roche calls offer for Illumina "starting point"
    n">Swiss drugmaker Roche Holding AG, in a letter to Illumina Inc shareholders, called its sweetened $51-a-share offer for the maker of genetic analysis equipment "a more than reasonable starting point for negotiations." The latest salvo
    2012-04-11 ROCHEILLUMINA
  • Roche seals licensing deal for antibiotic-boosting drug to battle superbugs

    Roche seals licensing deal for antibiotic-boosting drug to battle superbugs
    ZURICH Roche has boosted its efforts to tackle antibiotic resistance, striking a deal worth up to $750 million with Japan's Meiji Seika Pharma and Canada's Fedora for a drug that can restore the power of antibiotics to combat infections. The Swiss dr
    2015-01-13 ROCHEANTIBIOTICS
  • Diagnostics, Tamiflu help Roche full-year sales beat poll

    Diagnostics, Tamiflu help Roche full-year sales beat poll
    ZURICH Swiss drugmaker Roche ROG.VX expects sales and profits to grow at a similar pace to last year, after a strong performance by its diagnostics unit and flu drug Tamiflu helped full-year sales beat expectations. Stripping out the impact of curren
    2015-01-28 ROCHERESULTS
  • Two Indian states halt sales of Roche's Avastin drug

    Two Indian states halt sales of Roche's Avastin drug
    NEW DELHI Two Indian states have put sales of Swiss drugmaker Roche's blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat. Avastin is
    2016-01-19 INDIAROCHEAvastin
  • Novartis launches new Entresto trials in bid to boost sales

    Novartis launches new Entresto trials in bid to boost sales
    ZURICH Novartis's heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction. Novartis, which on Thursday described the trials as "the largest global
    2016-05-19 NOVARTISentresto
  • GSK, facing bribery claims, battles to build new sales model

    GSK, facing bribery claims, battles to build new sales model
    LONDON Drugmaker GlaxoSmithKline - hit by bribery claims in five countries - is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices. Following a decision to cut co
    2014-04-17 CORRUPTIONGSK
  • GSK pounces on Human Genome with $2.6 billion bid

    GSK pounces on Human Genome with $2.6 billion bid
    LONDON Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector recently swept by M&A activity. The U.S. pioneer of gene-based drug discove
    2012-04-19 HUMANGENOMEGSK
  • Roche profits rise, payout level prompts M&A questions

    Roche profits rise, payout level prompts M&A questions
    BASEL Roche offered shareholders a lower-than-expected dividend payout after reporting an 18 percent rise in full-year net profit, potentially a sign the Swiss pharmaceuticals group might be keeping its cash for deals. Roche - the world's largest mak
    2014-01-30 ROCHERESULTS
  • Long-serving Roche chairman to step down next year

    Long-serving Roche chairman to step down next year
    ZURICH Roche's influential Chairman Franz Humer said on Tuesday he will not stand for re-election next year when he will have served 16 years at the helm, potentially accelerating a shift of emphasis towards the Swiss drugmaker's U.S. operations. "Ro
    2013-03-05 ROCHECHAIRMAN

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated

  • Wie viel besser als ein Betäubungsmittel?

    Mein Dr. ist besorgt, dass ich auf einem Betäubungsmittel (percotete) gewesen, zu lange wegen Schmerzen, die durch zwei prall Scheiben L4 / L5 und S 1/2 verursacht zu unterstützen. Ich habe auf Gabapentin jetzt setzen. Ist das wirklich eine bessere s
  • Weiß jemand, ob es in Ordnung ist, die Antiflohmedizin "Revolution", eine Woche zu früh zu benutzen?

    Es wäre sonst bei guter Gesundheit für eine 9-jährige Katze sein. Sie scheint immer noch Flöhe haben. Ich benutzte es, auf ihrem 3. September 09. ----schneiden---- In Antwort auf snakelad ... bei 2009-09-29 00.59 Ich würde das nicht tun, wenn ich du
  • Frage zum Medikament?

    Ich bin jetzt seit ca. 5 Jahren auf Lisinopril-HCTZ 20-12,5 Tab gewesen. Ich trat Weight Watchers im Juli des vergangenen Jahres und haben 50 Pfund gesunken. so der Arzt Dabei hat mich aus der Medikation aufgrund mein Blutdruck ist jetzt gut gemacht.
  • Border inspectors to check for risky food, drug imports

    Border inspectors to check for risky food, drug imports
    WASHINGTON Border inspectors nationwide will soon start using a new computer system to identify risky food and medicine from abroad, the head of the U.S. Food and Drug Administration said on Thursday. The project follows recalls of tainted toothpaste
  • Schwere Verbrennungen Mai 'Bad Bakterien "Let übernehmen das Gut

    Schwere Verbrennungen Mai 'Bad Bakterien "Let übernehmen das Gut
    Credit: Kateryna Kon / Shutterstock.com Menschen, die schwere Verbrennungen bekommen haben, sind bekannt mit einem Risiko für eine Vielzahl von Komplikationen zu sein, aber es können auch andere Folgen lauern tiefer im Körper: Eine neue Studie stellt
  • Methotrexate - nach 2 Jahren macht immer noch müde und bedrückt, hat jemand anders diese Weise fühlen?

    Ich habe jetzt seit zwei Jahren Methotrexate genommen, und ich habe immer noch die Seite jede Woche Effekte. Ich fühle mich müder als jemals zuvor, und diese Lethargie mir verursacht hat, Gewicht zu gewinnen und etwas depressiv. Ich bin normalerweise
  • Wie lange dauert es, Elavil, um in Ihrem System?

    Ich begann Elavil 50mg Montag, und ich habe eine wandelnde Zombie gewesen und haben sehr deprimiert gewesen. Ich habe noch nie erlebt Depression. Mein Schmerz scheint sogar verschlechtern zu haben, anstatt besser. Ist das normal? ----schneiden---- In
  • Amlodipine - Gab es Studien über die langfristigen Auswirkungen der Nutzung ??

    Ich habe keine gesehen. ----schneiden---- In der Antwort auf Rajive G ... am 2012-08-08 23.10 Uhr Ich habe es seit den letzten 7 Jahren mit, es ist ein gut med gut vertragen., Ich glaube, Sie Rat von einem Apotheker / doc suchen sollte, die vielleich
  • Leiomyosarkom des Kolon und Rektum

    Leiomyosarkom des Kolon und Rektum
    Die Früherkennung von Leiomyosarkom des Kolon und Rektum ist entscheidend, weil der Krebs metastasiert (Spreads) in mehr als der Hälfte der Patienten. Allerdings ist eine frühe Diagnose häufig erst nach Komplikationen wie Blutungen oder Behinderung a
  • Schilddrüsen-Problem nach der Schwangerschaft: Postpartale Thyreoiditis

    Schilddrüsen-Problem nach der Schwangerschaft: Postpartale Thyreoiditis
    Es ist üblich, dass Frauen müde, Erfahrung Stimmungsschwankungen, zu fühlen und eine Vielzahl anderer Symptome in den Monaten nach der Geburt haben. Aber für einige Frauen kann Symptome lästig werden und zu einer Schilddrüsen-Problem als postpartale